Abstract
BackgroundGlioblastoma (GBM), the most malignant form of gliomas, is a relatively common primary brain tumor in adults. Preoperative identification of isocitrate dehydrogenase 1 (IDH1) mutations in GBM is of critical prognostic importance. The aim of the present study was to explore the feasibility and diagnostic performance of basic patient information combined with conventional magnetic resonance imaging (MRI) findings for determination of the IDH1 status (mutant vs wild type) in patients with GBM.MethodsFrom January 1, 2016 to December 31, 2017, a consecutive series of 50 patients with GBM was retrospectively collected. The patients were divided into two group according to their IDH1 mutation status. Basic information and MRI features were analyzed for the establishment of a diagnostic prediction model using logistic regression. A receiver operating characteristic curve was used to evaluate the diagnostic performance.ResultsPatients with IDH1-mutant tumors were younger than those with IDH1-wild type tumors, and exhibited a larger tumor volume. The diagnostic predictive model established by combining age and the tumor size exhibited a sensitivity and specificity of 70% and 93%, respectively. The area under the curve was 0.88, which indicated high diagnostic performance.ConclusionPatient age and tumor volume can be used as indicators of IDH1 mutation status in patients with GBM, with high diagnostic performance for simple evaluations in clinical practice. The combined use of these two indicators can further enhance the diagnostic specificity.
Highlights
Glioblastoma (GBM) is the most common and malignant form of gliomas and is associated with an extremely poor prognosis
Parsons et al (2008) reported that patients with IDH-mutant GBM had an average survival time of 3.8 years, while the average survival time of isocitrate dehydrogenase 1 (IDH1)-wild type patients was 1.1 years. These reports indicated that the IDH1 mutation status in patents with GBM was significantly correlated with the prognosis, and that preoperative identification of IDH1 mutations in GBM is of critical prognostic importance
The present study explored whether combination of basic patient information and conventional magnetic resonance imaging (MRI) finding can be used to determine the IDH1 status in GBM patients
Summary
Glioblastoma (GBM) is the most common and malignant form of gliomas and is associated with an extremely poor prognosis. Parsons et al (2008) reported that patients with IDH-mutant GBM had an average survival time of 3.8 years, while the average survival time of IDH1-wild type patients was 1.1 years These reports indicated that the IDH1 mutation status in patents with GBM was significantly correlated with the prognosis, and that preoperative identification of IDH1 mutations in GBM is of critical prognostic importance. The aim of the present study was to explore the feasibility and diagnostic performance of basic patient information combined with conventional magnetic resonance imaging (MRI) findings for determination of the IDH1 status (mutant vs wild type) in patients with GBM. Conclusion: Patient age and tumor volume can be used as indicators of IDH1 mutation status in patients with GBM, with high diagnostic performance for simple evaluations in clinical practice. The combined use of these two indicators can further enhance the diagnostic specificity
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
